Last updated: September 25, 2026
COZAAR, Merck’s brand of losartan potassium, moved from a high-value protected antihypertensive to a mature, low-cost generic market after U.S. patent expiry in 2010. Its commercial decline was driven primarily by generic substitution, therapeutic competition from other renin-angiotensin system drugs, and later manufacturing recalls involving nitrosamine contamination. Merck’s combined COZAAR and HYZAAR franchise generated roughly $3 billion to $4 billion annually before generic entry but no longer represents a material growth asset.
What is COZAAR and how does losartan work?
COZAAR is the brand name for losartan potassium, an oral angiotensin II receptor blocker, or ARB. The FDA approved COZAAR in April 1995 for hypertension. The product was later approved for diabetic nephropathy in patients with type 2 diabetes and hypertension, and for reduction of stroke risk in certain hypertensive patients with left ventricular hypertrophy.[1]
Losartan blocks the angiotensin II type 1 receptor. The mechanism reduces vasoconstriction and aldosterone activity, lowering blood pressure and reducing pressure on the cardiovascular and renal systems.
HYZAAR combines losartan with hydrochlorothiazide. The combination extends the franchise into patients requiring more than one antihypertensive mechanism.
| Product |
Active ingredient |
Initial U.S. approval |
Primary use |
Commercial status |
| COZAAR |
Losartan potassium |
1995 |
Hypertension and related cardiovascular indications |
Generic market |
| HYZAAR |
Losartan potassium/hydrochlorothiazide |
1995 |
Hypertension |
Generic combination market |
| Generic losartan |
Losartan potassium |
2010 onward |
Hypertension |
Multiple manufacturers |
| Generic losartan/HCTZ |
Losartan potassium/hydrochlorothiazide |
2010 onward |
Hypertension |
Multiple manufacturers |
What was COZAAR’s historical revenue trajectory?
COZAAR and HYZAAR were among Merck’s largest products before loss of exclusivity. Merck reported combined worldwide sales of approximately $3.6 billion in 2008. Sales declined as generic manufacturers entered the U.S. market and as the products faced competition from other ARBs, including valsartan, irbesartan, candesartan and telmisartan.[2]
The franchise’s historical trajectory can be divided into four phases.
Protected growth before generic entry
From the late 1990s through the mid-2000s, COZAAR benefited from broad hypertension prevalence, physician familiarity with ARBs and expansion of the HYZAAR combination product. Merck marketed the franchise as a long-term cardiovascular therapy with renal benefits in diabetic nephropathy.
The product competed against ACE inhibitors and other ARBs. ARBs often gained share among patients who developed cough or intolerance with ACE inhibitors.
Peak commercial period
COZAAR and HYZAAR reached their highest commercial value shortly before generic entry. Merck’s reported combined sales were approximately:
| Year |
Approximate COZAAR/HYZAAR sales |
Market condition |
| 2007 |
$3.4 billion |
Protected branded market |
| 2008 |
$3.6 billion |
Near peak sales |
| 2009 |
Approximately $3.2 billion |
Pre-expiry erosion beginning |
| 2010 |
Approximately $2.6 billion |
U.S. generic entry |
| 2011 |
Approximately $1.8 billion |
Accelerated generic substitution |
| After 2011 |
Materially lower |
Mature generic market |
Reported figures vary by Merck’s geographic and product aggregation conventions. Merck later stopped treating COZAAR and HYZAAR as major growth products in its public financial reporting.[2]
Patent expiry and rapid erosion
U.S. generic entry began in 2010 after expiry of the principal losartan patent protection. Brand revenue fell sharply because losartan tablets were relatively simple to manufacture, had extensive clinical use and were readily substitutable under pharmacy benefit rules.
Generic entry affected both COZAAR and HYZAAR. Combination products generally retained some branded demand, but the availability of generic losartan/hydrochlorothiazide limited the duration of that protection.
Mature generic phase
The current market is defined by high generic penetration, low unit prices and procurement competition. Revenue is distributed among generic manufacturers, wholesalers, pharmacies and health plans rather than concentrated in the original brand owner.
The commercial value of branded COZAAR now comes mainly from residual prescribing, institutional purchasing, legacy brand recognition and markets where branded reimbursement remains available. It is not a significant growth platform for Merck.
When did COZAAR lose U.S. patent exclusivity?
The principal U.S. losartan patent was U.S. Patent No. 5,138,069, assigned to E. I. du Pont de Nemours and Company. The patent covered losartan and related compounds and was filed in the early 1990s. Its ordinary term expired in 2010 after applicable patent-term adjustments and pediatric exclusivity.
| Protection category |
Relevant information |
| Active ingredient |
Losartan potassium |
| Principal U.S. patent |
U.S. Patent No. 5,138,069 |
| Patent holder history |
DuPont-originated technology; commercial rights associated with Merck |
| U.S. approval |
1995 |
| Principal U.S. patent expiry |
2010 |
| Generic entry |
2010 |
| Current status |
Core U.S. composition protection expired |
The loss of exclusivity did not remove every patent claim associated with losartan products at the same time. Formulation, combination-product, manufacturing and method-of-use patents can have separate expiration dates. Those later rights did not preserve the original commercial economics because generic manufacturers could enter the base losartan market.
What patents protect COZAAR and HYZAAR?
The core patent estate covered the losartan chemical class and pharmaceutical use. Later protection addressed specific formulations, combinations and treatment applications.
Core compound patents
The principal asset was the losartan compound patent. It established the primary exclusivity period for COZAAR and supported the commercial launch of the ARB franchise.
Method-of-use patents
COZAAR labeling included uses beyond uncomplicated hypertension, including diabetic nephropathy and certain stroke-risk reduction claims. Method-of-use protection can be relevant to patent litigation and paragraph IV certifications, but it generally has less commercial strength after generic approval because of:
- Label carve-outs for patented indications.
- Physician prescribing outside the patented indication.
- The availability of losartan for non-patented hypertension uses.
- The difficulty of proving induced infringement in routine generic substitution.
Combination-product patents
HYZAAR combines losartan with hydrochlorothiazide. Combination patents can delay or complicate generic approval if they remain enforceable, but the losartan/hydrochlorothiazide market ultimately developed as a generic product category.
Formulation and manufacturing protection
Losartan tablets contain a mature active pharmaceutical ingredient with established manufacturing processes. Any later formulation or process patents had limited ability to block all generic competition. Generic firms could use alternative excipients, processes or suppliers if their products met FDA requirements and avoided valid patent claims.
What is the Orange Book status of COZAAR?
COZAAR is an FDA-approved prescription drug with historical Orange Book listings associated with Merck’s NDA. The relevant commercial significance of the Orange Book listing has diminished because the principal patent protection expired and generic products are widely approved.
The Orange Book identifies patents and exclusivity associated with approved drug products. It does not guarantee that a listed patent will withstand challenge, and it does not prevent generic entry after expiry or successful resolution of patent litigation.[3]
For losartan, the critical regulatory event was the transition from an NDA-controlled branded product to multiple ANDA-approved generic products. Generic applicants could certify against listed patents under paragraph IV or wait until patent expiry under other certification pathways.
Which companies challenged COZAAR exclusivity?
The principal competitive pressure came from generic manufacturers filing ANDAs for losartan and losartan/hydrochlorothiazide. Major generic suppliers in the U.S. market have included companies such as:
- Teva Pharmaceuticals
- Mylan, now part of Viatris
- Sandoz
- Dr. Reddy’s Laboratories
- Torrent Pharmaceuticals
- Lupin
- Zydus Pharmaceuticals
- Aurobindo Pharma
- Solco Healthcare
- Rising Pharmaceuticals
The precise manufacturer mix has changed over time because of supply agreements, product discontinuations, FDA inspections and recalls.
Generic entry was commercially more important than any single litigation outcome. Once several ANDA products became available, pharmacies and payers had substantial leverage to substitute away from the Merck brand.
What generic entry risks affect COZAAR?
COZAAR has no meaningful remaining U.S. generic-entry risk because generic entry has already occurred. The relevant issue is ongoing erosion of branded demand and supply continuity in the generic market.
| Risk |
Current effect |
| New generic launch |
Low incremental impact because the market is already genericized |
| Brand-to-generic substitution |
Persistent and substantial |
| Price compression |
High |
| Manufacturer consolidation |
Can increase supply concentration |
| API supply disruption |
Can cause temporary shortages or allocation |
| Recall activity |
Can shift demand among generic suppliers |
| Therapeutic substitution |
Moderate, based on ARB and antihypertensive alternatives |
COZAAR is vulnerable to substitution by generic losartan, generic valsartan, generic irbesartan and other antihypertensive classes. Clinical interchangeability is not identical across all products, but payer formularies and pharmacy substitution strongly favor low-cost generic options.
How did NDMA recalls affect the losartan market?
Beginning in 2018, regulators and manufacturers identified nitrosamine impurities in certain ARB products. The issue initially centered on valsartan but later affected some losartan and irbesartan batches. FDA testing found that contamination depended on the manufacturer, API source, process and batch rather than on every losartan product.[4]
The recalls had four commercial effects:
- Patients and pharmacies shifted between generic manufacturers.
- Wholesalers increased scrutiny of API sources and batch testing.
- Some suppliers experienced temporary shortages or allocation pressure.
- Brand products gained limited short-term attention but did not recover their former market position.
The recall episode increased manufacturing and quality-assurance costs. It did not restore COZAAR’s lost patent exclusivity or materially change the long-term generic economics.
What is the competitive landscape for losartan?
Losartan competes in three overlapping markets.
ARB competition
Losartan competes with generic valsartan, irbesartan, candesartan, telmisartan and olmesartan. Losartan remains widely used because of its low cost, clinical familiarity and availability in combination products.
ACE inhibitor competition
Lisinopril and other ACE inhibitors remain major alternatives. ACE inhibitors are often selected first for hypertension, diabetes or heart failure depending on clinical circumstances. Losartan may be selected when cough or other ACE inhibitor intolerance is a concern.
Fixed-dose combination competition
Losartan competes with combinations such as:
- Losartan/hydrochlorothiazide
- Valsartan/hydrochlorothiazide
- Irbesartan/hydrochlorothiazide
- Amlodipine/losartan
- Other antihypertensive combinations
Fixed-dose combinations can improve adherence but face intense generic price competition.
How strong is the COZAAR patent estate?
The current patent strength is weak because the primary U.S. exclusivity period expired and generic products are established. Historically, the estate was commercially strong because it combined compound protection with regulatory approval, physician adoption and a large hypertension population.
| Patent-strength factor |
Assessment |
| Core compound protection |
Expired |
| Formulation protection |
Limited current blocking value |
| Method-of-use protection |
Narrow and difficult to enforce broadly |
| Generic design-around potential |
High |
| Remaining U.S. exclusivity |
None of material commercial significance |
| Manufacturing barriers |
Moderate operational complexity, low legal exclusivity |
| Biosimilar barrier |
Not applicable |
Losartan is a small-molecule drug, not a biologic. Biosimilar risk does not apply. The relevant competitive pathway is the abbreviated new drug application, or ANDA, rather than the biosimilar pathway under the Public Health Service Act.
What FDA regulatory status applies to COZAAR?
COZAAR is an FDA-approved small-molecule prescription drug. Its core indications include hypertension and diabetic nephropathy in specified patient populations. HYZAAR is an FDA-approved fixed-dose combination.
The principal regulatory distinctions are:
- COZAAR is approved under an NDA.
- Generic losartan products are approved under ANDAs.
- Generic losartan/hydrochlorothiazide products are also approved under ANDAs.
- No biosimilar framework applies.
- FDA approval does not protect the product from therapeutic substitution once patents and regulatory exclusivities expire.
What licensing deals shaped COZAAR?
Losartan originated from research associated with DuPont. Merck commercialized the product through its relationship with DuPont and associated pharmaceutical operations. The product became part of Merck’s cardiovascular portfolio and was marketed globally as COZAAR and HYZAAR.
The historic licensing and commercialization arrangement was strategically important because it paired DuPont’s discovery work with Merck’s global regulatory, manufacturing and sales capabilities. That arrangement has little current impact on generic competition because the core exclusivity period has ended.
What litigation and settlement agreements affected COZAAR?
COZAAR faced the standard patent-certification risks associated with a major small-molecule product approaching loss of exclusivity. Generic applicants could submit paragraph IV certifications asserting that listed patents were invalid, unenforceable or not infringed.
The commercial outcome was generic availability in 2010. Publicly visible litigation connected with losartan patent rights did not preserve a durable branded monopoly after that date. The current market does not depend on an active patent settlement that controls U.S. generic entry.
The more consequential legal and regulatory events in the mature market have involved product quality, recalls, supplier qualification and pharmaceutical manufacturing compliance rather than core patent exclusion.
How does COZAAR compare with competing antihypertensive drugs?
| Drug or class |
Patent position |
Generic penetration |
Main commercial advantage |
| COZAAR/losartan |
Expired |
Very high |
Low cost and familiarity |
| Valsartan |
Expired |
Very high |
Broad use and combinations |
| Irbesartan |
Expired |
Very high |
Diabetic nephropathy positioning |
| Candesartan |
Expired |
High |
Clinical use in hypertension and heart failure |
| Lisinopril |
Expired |
Very high |
Low cost and broad physician use |
| Amlodipine |
Expired |
Very high |
Strong efficacy and combination use |
| Branded ARBs |
Mostly mature or genericized |
Variable |
Residual brand positioning |
Losartan’s most durable advantages are price, availability and familiarity. Its disadvantages include low manufacturer margins, substantial substitution pressure and limited ability for the original brand owner to differentiate the product.
What is the financial outlook for COZAAR?
COZAAR’s financial trajectory is mature to declining from the perspective of the brand owner. Future brand revenue is unlikely to approach the pre-2010 peak without a major change in reimbursement, supply conditions or product strategy.
The revenue pool now resides primarily in generic volume. Financial performance depends on:
- Prescription volume for losartan and combination products.
- Average selling price erosion.
- Manufacturer count and market concentration.
- API costs and supply reliability.
- FDA compliance and recall exposure.
- Payer formulary placement.
- Hospital and wholesaler contracting.
Generic manufacturers can generate acceptable returns through scale and efficient supply, but losartan is unlikely to provide the margins associated with a protected branded medicine. For Merck, COZAAR is a legacy product rather than a significant contributor to growth, licensing value or pipeline valuation.
What geographic coverage remains for COZAAR?
The original COZAAR franchise achieved broad international coverage. Patent expiry occurred on a country-by-country basis, and local market entry depended on national regulatory approval, patent terms and reimbursement systems.
In most major markets, losartan is now available from multiple generic manufacturers. Brand retention varies by country based on:
- National substitution rules.
- Public reimbursement.
- Physician prescribing habits.
- Local patent and regulatory history.
- Brand loyalty.
- Government procurement practices.
Emerging markets may retain branded or semi-branded losartan products, but low-price generic competition remains the dominant long-term trend.
Key Takeaways
- COZAAR is Merck’s brand of losartan potassium, an ARB approved in the U.S. in 1995.
- COZAAR and HYZAAR generated approximately $3.6 billion in combined sales in 2008 before generic erosion.
- The principal U.S. losartan patent, U.S. Patent No. 5,138,069, expired in 2010.
- Generic losartan and losartan/hydrochlorothiazide products entered the U.S. market in 2010 and rapidly reduced branded revenue.
- The product has no meaningful biosimilar risk because losartan is a small-molecule drug.
- Current competitive pressure comes from generic ARBs, ACE inhibitors and fixed-dose antihypertensive combinations.
- NDMA-related recalls disrupted selected generic suppliers but did not restore branded exclusivity.
- COZAAR’s patent estate has low current blocking strength, while manufacturing and supply-chain execution remain the main operational issues.
- The franchise is commercially mature, with value concentrated in generic volume rather than branded pricing power.
FAQs
Is COZAAR still sold in the United States?
Yes. Brand COZAAR remains an FDA-approved product, but most U.S. prescriptions are filled with generic losartan rather than the Merck brand.
Is losartan the same as COZAAR?
Losartan is the active ingredient in COZAAR. Generic losartan is therapeutically equivalent to the approved brand when supplied by an FDA-approved manufacturer and used according to labeling.
Did COZAAR have orphan-drug exclusivity?
No. COZAAR was approved for common cardiovascular and renal indications and did not depend on orphan-drug exclusivity.
Can a generic manufacturer launch losartan without infringing COZAAR patents?
Yes. The relevant core U.S. patent protection expired, and multiple generic losartan products have been approved and marketed. Any later patent analysis must examine the specific product, formulation, method of use and jurisdiction.
Does Merck still have a major financial exposure to COZAAR?
No. COZAAR and HYZAAR were historically important Merck products, but generic entry removed most of the franchise’s branded revenue and reduced its strategic financial significance.
References
-
U.S. Food and Drug Administration. (2023). COZAAR (losartan potassium) prescribing information. FDA.
-
Merck & Co., Inc. (2008-2011). Annual reports. Merck & Co.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2020). FDA updates and press announcements on nitrosamine impurities in angiotensin II receptor blockers. FDA.
-
U.S. Patent and Trademark Office. (1992). U.S. Patent No. 5,138,069: Substituted imidazole compounds as angiotensin II receptor antagonists. USPTO.
